You have full text access to this OnlineOpen article

Tissue plasminogen activator antigen is strongly associated with myocardial infarction in young women

  1. P. M. MANNUCCI1,
  2. L. BERNARDINELLI1,
  3. L. FOCO1,
  4. M. GALLI2,
  5. F. RIBICHINI3,
  6. M. TUBARO4,
  7. F. PEYVANDI1

Article first published online: 25 JAN 2005

DOI: 10.1111/j.1538-7836.2005.01116.x

Issue

Journal of Thrombosis and Haemostasis

Journal of Thrombosis and Haemostasis

Volume 3, Issue 2, pages 280–286, February 2005

Additional Information

How to Cite

MANNUCCI, P. M., BERNARDINELLI, L., FOCO, L., GALLI, M., RIBICHINI, F., TUBARO, M. and PEYVANDI, F. (2005), Tissue plasminogen activator antigen is strongly associated with myocardial infarction in young women. Journal of Thrombosis and Haemostasis, 3: 280–286. doi: 10.1111/j.1538-7836.2005.01116.x

Author Information

  1. 1

    Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione Luigi Villa and Department of Internal Medicine and Dermatology, IRCCS Maggiore Hospital and University of Milano; Department of Health Sciences, Section of Medical Statistics and Epidemiology, University of Pavia

  2. 2

    Division of Cardiology, ASL6 Hospital of Livorno

  3. 3

    Catheterization Laboratory, Maggiore Hospital and East Piedmont University, Novara

  4. 4

    Coronary Care Unit, Cardiovascular Department, San Filippo Neri Hospital, Rome, Italy

*P.M. Mannucci, Via Pace 9, 20122 Milan, Italy. Tel.: +39 02 55035421; fax: +39 0250320723; e-mail: pmmannucci@libero.it

Publication History

  1. Issue published online: 25 JAN 2005
  2. Article first published online: 25 JAN 2005
  3. Received 8 September 2004, accepted 11 October 2004

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (136K)

References

  • 1
    Choudhury L, Marsh JD. Myocardial infarction in young patients. Am J Med 1999; 107: 254–61.
  • 2
    Mukherjee D, Hsu A, Moliterno DJ, Lincoff AM, Goormastic M, Topol EJ. Risk factors for premature coronary artery disease and determinants of adverse outcomes after revascularization in patients ≤ 40 years old. Am J Cardiol 2003; 92: 1465–7.DOI: 10.1016/j.amjcard.2003.08.062
  • 3
    Stamler J, Stamler R, Neaton JD, Wentworth D, Daviglus ML, Garside D, Dyer AR, Liu K, Greenland P. Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. JAMA 1999; 282: 2012–18.DOI: 10.1001/jama.282.21.2012
  • 4
    Kullo IJ, Gau GT, Tajik AJ. Novel risk factors for atherosclerosis. Mayo Clin Proc 2000; 75: 369–80.
  • 5
    Zimmerman FH, Cameron A, Fisher LD, Ng G. Myocardial infarction in young adults. angiographic characterization, risk factors and prognosis (Coronary Artery Surgery Study Registry). J Am Coll Cardiol 1995; 26: 654–61.DOI: 10.1016/0735-1097(95)00254-2
  • 6
    Chen L, Chester M, Kaski JC. Clinical factors and angiographic features associated with premature coronary artery disease. Chest 1995; 108: 364–9.
  • 7
    Kanitz MG, Giovannucci SJ, Jones JS, Mott M. Myocardial infarction in young adults: risk factors and clinical features. J Emerg Med 1996; 14: 139–45.DOI: 10.1016/0736-4679(95)02089-6
  • 8
    Atherosclerosis Thrombosis and Vascular Biology Italian Study Group. No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. Circulation 2003; 107: 1117–22.
  • 9
    Folsom AR. Hemostatic risk factors for atherothrombotic disease: an epidemiologic view. Thromb Haemost 2001; 86: 366–73.
  • 10
    Reiner AP, Siscovick DS, Rosendaal FR. Hemostatic risk factors and arterial thrombotic disease. Thromb Haemost 2001; 85: 584–95.
  • 11
    Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994; 331: 417–24.DOI: 10.1056/NEJM199408183310701
  • 12
    Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973–9.DOI: 10.1056/NEJM199704033361401
  • 13
    Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731–3.
  • 14
    Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, Hutchinson WL, Pepys MB. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men. results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984–92. Circulation 1999; 99: 237–42.
  • 15
    Frezzato M, Tosetto A, Rodeghiero F. Validated questionnaire for the identification of previous personal or familial venous thromboembolism. Am J Epidemiol 1996; 143: 1257–65.
  • 16
    Nordenhem A, Wiman B. Tissue plasminogen activator (tPA) antigen in plasma: correlation with different tPA/inhibitor complexes. Scand J Clin Laboratory Invest 1998; 58: 475–83.DOI: 10.1080/00365519850186274
  • 17
    Jansson JH, Nilsson TK, Olofsson BO. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J 1991; 12: 157–61.
  • 18
    Thompson SG, Kienast J, Pyke SD, Haverkate F, Van De Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332: 635–41.DOI: 10.1056/NEJM199503093321003
  • 19
    Held C, Hjemdahl P, Rehnqvist N, Wallen NH, Bjorkander I, Eriksson SV, Forslund L, Wiman B. Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol. Results from the Angina Prognosis study in Stockholm. Circulation 1997; 95: 2380–6.
  • 20
    Wiman B, Andersson T, Hallqvist J, Reuterwall C, Ahlbom A, DeFaire U. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. Arterioscler Thromb Vasc Biol 2000; 20: 2019–23.
  • 21
    Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341: 1165–8.DOI: 10.1016/0140-6736(93)90998-V
  • 22
    Jansson JH, Norberg B, Nilsson TK. Impact of acute phase on concentrations of tissue plasminogen activator and plasminogen activator inhibitor in plasma after deep-vein thrombosis or open-heart surgery. Clin Chem 1989; 35: 1544–5.
  • 23
    Seljeflot I, Tonstad S, Hjermann I, Arnesen H. Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease. Thromb Res 2002; 105: 285–90.DOI: 10.1016/S0049-3848(02)00034-8
  • 24
    Son JW, Koh KK, Ahn JY, Jin DK, Park GS, Kim DS, Shin EK. Effects of statin on plaque stability and thrombogenicity in hypercholesterolemic patients with coronary artery disease. Int J Cardiol 2003; 88: 77–82.DOI: 10.1016/S0167-5273(02)00368-6
  • 25
    Krysiak R, Okopien B, Herman Z. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs 2003; 63: 1821–54.
  • 26
    Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100: 230–5.
  • 27
    Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001; 103: 1191–3.
View Full Article (HTML) Get PDF (136K)